Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

342.20 +9.32 (+2.80%)
Streaming Delayed Price Updated: 1:17 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Bio-Rad Laboratories, inc (BIO) Q2 2021 Earnings Call Transcript ↗
BIO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Recap: Bio-Rad Laboratories Q2 Earnings ↗
Shares of Bio-Rad Laboratories (NYSE:BIO) moved higher by 0.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 119.88%... 
Via Benzinga
News headline image
Bio-Rad Reports Second-Quarter 2021 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Highs On Tuesday ↗
This morning 85 companies set new 52-week highs. Noteworthy Mentions: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ:GOOG). Intec... 
Via Benzinga
News headline image
Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Announces Partnership with Seegene for Molecular Diagnostic Testing Products
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Launches Its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit for COVID-19 Wastewater Testing
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
News headline image
Bio-Rad to Participate at Jefferies Virtual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
5 Value Stocks In The Healthcare Sector ↗
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
News headline image
Bio-Rad Laboratories Inc (BIO) Q1 2021 Earnings Call Transcript ↗
BIO earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Bio-Rad Reports First-Quarter 2021 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
News headline image
A Preview Of Bio-Rad Laboratories's Earnings ↗
On Thursday, April 29, Bio-Rad Laboratories (NYSE:BIO) will release its latest earnings report. Here is Benzinga's outlook for the company. What Are Earnings, Net Income, And... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx ↗
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
News headline image
Bio-Rad to Report First-Quarter 2021 Financial Results, Thursday, April 29, 2021
From Bio-Rad Laboratories, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.